Format

Send to

Choose Destination
Pediatr Transplant. 2014 Mar;18(2):E44-7. doi: 10.1111/petr.12206. Epub 2013 Dec 16.

Eculizumab reverses the potentially fatal effects of kidney graft reperfusion injury.

Author information

1
Department of Kidney Transplantation, National Research Center for Surgery, Moscow, Russian Federation.

Abstract

Half an hour after reperfusion, the kidney, transplanted to the infant from an adult brain dead standard criteria donor, became flabby and acquired blue color. Hyperacute rejection was suspected as a consequence of false negative cross match, and eculizumab was administered with the purpose to treat antibody-mediated injury, with fast and clear effect. The patient's blood was tested for donor-specific antibodies on the next day, and results were negative. We attribute graft damage to reperfusion injury and explain eculizumab's effectiveness to its ability to prevent progression of reperfusion injury.

KEYWORDS:

antibody induction; hyperacute rejection; kidney transplantation; reperfusion injury

PMID:
24330127
DOI:
10.1111/petr.12206
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center